Olanzapine-based steroid-sparing anti-nausea treatment for breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new anti-nausea medicine combination for breast cancer patients getting AC chemotherapy, specifically designed for those with diabetes, obesity, or other metabolic issues. It aims to reduce the need for steroids, which can be riskier for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have stage I to III breast cancer.
- You are scheduled to receive AC chemotherapy (a common breast cancer treatment).
- You have at least one metabolic risk factor such as diabetes, prediabetes, obesity, or metabolic syndrome.
- You are generally able to care for yourself (ECOG performance status 2 or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if combining two anti-nausea drugs (olanzapine and palonosetron) can prevent vomiting and nausea without using steroids in people receiving high-dose cisplatin chemotherapy for their first time.
This study tests whether a medicine called olanzapine can improve survival in people with advanced cancers of the upper digestive system or lungs. Olanzapine may help with appetite and weight, which are common problems in these cancers.
This trial tests if giving anti-nausea drugs based on your genetic makeup can better prevent vomiting and nausea from chemotherapy for early breast cancer. You will receive a personalized regimen tailored to your pharmacogenetic profile.
This trial tests whether the drug olanzapine can help reduce side effects of chemotherapy when given before surgery for stomach cancer, potentially helping patients feel better and complete their treatment.
This study tests whether olanzapine, a medication that can increase appetite, helps prevent severe appetite loss and muscle wasting in patients with ovarian or stomach cancer who are receiving chemotherapy before surgery. The goal is to help patients maintain nutrition and strength during treatment.
This trial tests if the drug olanzapine can help improve appetite in people with head and neck cancer who are getting chemotherapy and radiation. It aims to prevent or reduce weight loss during treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.